Trial Profile

A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC98 For Injection in Subjects With Advanced Malignant Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 29 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RC 98 (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors RemeGen

Most Recent Events

24 Nov 2023 Planned primary completion date changed from 28 Dec 2022 to 28 Dec 2023.
24 Nov 2023 Status changed from recruiting to active, no longer recruiting.
07 Mar 2022 Planned End Date changed from 30 Mar 2022 to 30 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com